BPC-157

What does research show about BPC-157?

Almost everything known comes from animal and laboratory studies. A 2026 review of three decades of that work reports regenerative effects across several organ systems, but counts fewer than 30 people ever studied, all in uncontrolled pilot studies, with no approved formulation, no validated dose and no completed Phase II trial [4]. Its plasma half-life is under 30 minutes, yet reported effects last hours to days, a gap researchers say is unresolved [4].

Is BPC-157 legal or FDA-approved?

Neither. A pharmacy may compound from a bulk substance under section 503A only if it has a USP monograph, is part of an FDA-approved drug, or is on the 503A bulks list [2]. BPC-157 is none of these; FDA placed it in Category 2 for potential safety risks before its nomination was withdrawn [1]. On July 23, 2026, FDA's Pharmacy Compounding Advisory Committee voted 8 to 6, with one abstention, to recommend adding it [3]. The vote is non-binding, and FDA has not acted.

Is BPC-157 safe?

Nobody knows, and FDA says so: it found no or only limited safety information for the proposed routes, flags a risk of immunogenicity for some of them, and notes peptide-impurity and characterization problems [1]. Products sold today are not FDA-verified for safety, effectiveness or quality. No validated human dose exists [4], so this page gives none.